<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87366">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936051</url>
  </required_header>
  <id_info>
    <org_study_id>H-1109-086-378</org_study_id>
    <secondary_id>2011-0931</secondary_id>
    <nct_id>NCT01936051</nct_id>
  </id_info>
  <brief_title>Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients</brief_title>
  <official_title>Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry for Health, Welfare and Family Affairs</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To modeling the pharmacokinetic-pharmacodynamic(PK-PD) simulation with the plasma
      concentration and the transporter occupancy from OCD patients treated with escitalopram.

      To examine the effect of G2677T/A single nucleotide polymorphism(SNP) of ABCB1 gene to the
      PK-PD modeling in OCD patients treated with escitalopram.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To measure plasma concentration of escitalopram in OCD patients treated with escitalopram.

      To measure serotonin transporter occupancy by escitalopram in OCD patients treated with
      escitalopram.

      To genotype G2677T/A SNP of ABCB1 gene in OCD patients treated with escitalopram.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>serotonin transporter occupancy</measure>
    <time_frame>72hr after oral administration of escitalopram</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>genotype</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yale-Brown Obsessive Compulsive Scale(Y-BOCS) Score</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>scale for the severity of Obsessive-compulsive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serotonin transporter occupancy</measure>
    <time_frame>within the first 24hrs after oral administration of escitalopram</time_frame>
    <safety_issue>No</safety_issue>
    <description>serotonin transporter occupancy measured at 5 hour and 24 hour after oral dose of escitalopram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>escitalopram plasma concentration</measure>
    <time_frame>within 72 hours after oral administration of escitalopram</time_frame>
    <safety_issue>No</safety_issue>
    <description>plasma concentration of escitalopram at baseline, 1, 2, 3, 5, 8, 10, 24, 48, 72 hour after oral dose of escitalopram</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>OCD</condition>
  <arm_group>
    <arm_group_label>OCD patients</arm_group_label>
    <description>OCD patients being treated with any dose of escitalopram</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        OCD patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of OCD based on Diagnostic and Statistical Manual(DSM)-IV criteria

          -  no change of escitalopram dosage in 6 weeks

        Exclusion Criteria:

          -  psychiatric comorbidity other than OCD

          -  History of head injury, epilepsy, other general medical disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Soo Kwon, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Woo Park, M.D.</last_name>
    <phone>82-19-426-4506</phone>
    <email>parkjinu78@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Euitae Kim, M.D., Ph.D.</last_name>
    <phone>82-10-9419-1058</phone>
    <email>euitae.kim@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Woo Park, MD</last_name>
      <phone>82-2-3668-7666</phone>
      <email>parkjinu78@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Soo Kwon, MD, PhD</last_name>
      <phone>82-2-2072-2450</phone>
    </contact_backup>
    <investigator>
      <last_name>Jun Soo Kwon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Euitae Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 2, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jun Soo Kwon</investigator_full_name>
    <investigator_title>Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in OCD Patients</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
